SHAREHOLDERS' EQUITY (Details Textual) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended		12 Months Ended
	Feb. 19, 2021 ₪ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 $ / shares	Dec. 31, 2015 $ / shares	Dec. 31, 2021 shares	Feb. 19, 2021 $ / shares shares	Dec. 28, 2016 USD ($)
Shareholders' Equity (Textual)
Description of wainwright or its designees warrants to purchase		the Company signed a purchase agreement with certain institutional investors for the issuance and sale of 15,403,014 ordinary shares, par value NIS 0.25 per share, pre-funded warrants to purchase up to an aggregate of 610,504 ordinary shares and ordinary warrants to purchase up to an aggregate of 8,006,759 ordinary shares at an exercise price of $2.00 per share. The Pre-Funded Warrants have an exercise price of $0.001 per Ordinary Share and are immediately exercisable and can be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. Each ordinary share was sold at an offering price of $2.035 and each pre-funded warrant was sold at an offering price of $2.034 (equal to the purchase price per ordinary share minus the exercise price of the pre-funded warrant). The offering of the ordinary shares, the pre-funded warrants and the ordinary shares that are issuable from time to time upon exercise of the pre-funded warrants was made pursuant to the Company’s shelf registration statement on Form S-3 initially filed with the Securities and Exchange Commission (“SEC”) on May 9, 2019, and declared effective by the SEC on May 23, 2019, and the ordinary warrants were issued in a concurrent private placement. The ordinary warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending five and one-half years from the date of issuance. All of the pre-funded warrants were exercised in full on September 27, 2021, and the offering closed on September 29, 2021. Additionally, the Company issued warrants to purchase up to 960,811 ordinary shares, with an exercise price of $2.5438 per share, exercisable from September 27, 2021, until September 27, 2026, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our September 2021 registered direct offering.
Securities Purchase Agreements [Member]
Shareholders' Equity (Textual)
Number of warrants issued		9,814,754
Warrants exercisable, description		exercisable from February 19, 2021 until August 26, 2026.
Total gross exercised | $		$ 13,800
Securities Purchase Agreements [Member] | Minimum [Member]
Shareholders' Equity (Textual)
Exercise price per share | $ / shares		$ 1.25
Securities Purchase Agreements [Member] | Maximum [Member]
Shareholders' Equity (Textual)
Exercise price per share | $ / shares		$ 1.79
Certain institutional purchasers [Member] | Offering of ordinary shares in February 2020 [Member]
Shareholders' Equity (Textual)
Number of warrants issued		3,740,100
Proceeds from warrants | $		$ 4,675,125
Certain institutional purchasers [Member] | Registered direct offering of ordinary shares in July 2020 [Member]
Shareholders' Equity (Textual)
Number of warrants issued		2,020,441
Proceeds from warrants | $		$ 3,555,976
Certain institutional purchasers [Member] | Offering of ordinary shares in December 2020 [Member]
Shareholders' Equity (Textual)
Number of warrants issued		3,598,072
Proceeds from warrants | $		$ 4,821,416
Placement agent [Member] | February 2020 best efforts offering [Member]
Shareholders' Equity (Textual)
Number of warrants issued		230,160
Proceeds from warrants | $		$ 359,625
Placement agent [Member] | December 2020 private placement [Member]
Shareholders' Equity (Textual)
Number of warrants issued		225,981
Purchase agreement with certain institutional investors [Member]
Shareholders' Equity (Textual)
Exercise price per share | $ / shares						$ 3.6
Number of warrants issued	5,460,751					5,460,751
Issuance of ordinary shares, shares	10,921,502
Exercise price ordinary shares | $ / shares						$ 3.6625
Purchase agreement with certain institutional investors [Member] | Additionally Warrants Issued [Member]
Shareholders' Equity (Textual)
Exercise price per share | $ / shares						$ 4.578125
Number of warrants issued	655,290					655,290
Purchase agreement with certain institutional investors [Member] | NIS [Member]
Shareholders' Equity (Textual)
Exercise price ordinary shares | ₪ / shares	₪ 0.25
Kreos Capital V [Member]
Shareholders' Equity (Textual)
Warrants grant date				Dec. 31, 2015
Warrants exercisable, description		currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of June 30, 2022.
Kreos Capital [Member]
Shareholders' Equity (Textual)
Exercise price per share | $ / shares				$ 7.5
Drawdown amount under loan agreement | $							$ 8,000
Employee Stock Option [Member]
Shareholders' Equity (Textual)
Award vesting period, description		Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year.
Shares reserved for future issuance (in shares)		364,701			233,957
Unrecognized cost of shares | $		$ 1,300
Expected term of shares		2 years 6 months
Restricted Stock Units (RSUs) [Member]
Shareholders' Equity (Textual)
Weighted average grant date fair value, options (in USD per share) | $ / shares		$ 1.14	$ 1.75